title: Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes.
abstract: BACKGROUND
  Obesity has been reported as risk factor for reduced posttransplant graft and patient survival and increased delayed graft function (DGF).
  
  
  OBJECTIVE
  The purpose of this work is to analyze the effect of body mass index (BMI) on defined transplant outcomes in patients transplanted under defined guidelines in a kidney transplant program.
  
  
  METHODS
  Review of a prospectively collected database in renal transplant recipients receiving rabbit antithymocyte globulin induction, mycophenolate mofetil, tacrolimus, and early corticosteroid withdrawal between 2001 and 2011.
  
  
  METHODS
  This review was conducted in a single abdominal transplant program in the United States.
  
  
  METHODS
  Primary outcome was death-censored graft survival categorized by posttransplant body mass groups. Secondary outcomes included DGF as well as patient survival.
  
  
  RESULTS
  Four hundred sixty seven patients were identified. No difference was observed in graft survival or DGF between BMI groups. One-year, death-censored graft survival and patient survival rates ranged from 97.5% to 100% and 96.6% to 100%, respectively. Delayed graft function was uncommon across all BMI groups, ranging from 5.3% to 9.1%, with the lowest incidence in patients with a BMI ≥ 35 kg/m(2). Biopsy-proven acute rejection rates at 1 year were similar across all groups (10.1%-14%) as were estimated glomerular filtration rates were at 1, 3, and 5 years.
  
  
  CONCLUSIONS
  Our results do not show an effect of BMI on posttransplant outcomes, suggesting that relaxation of BMI criteria may be warranted for recipient selection.
authors.affiliation: Division of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA simon.tremblay.1@gmail.com.
authors.forename: Simon
authors.initials: S
authors.lastname: Tremblay
authors.affiliation: Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
authors.forename: Tiffany E
authors.initials: TE
authors.lastname: Kaiser
authors.affiliation: Division of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
authors.forename: Rita R
authors.initials: RR
authors.lastname: Alloway
authors.affiliation: Division of Transplantation, Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.
authors.forename: E Steve
authors.initials: ES
authors.lastname: Woodle
authors.affiliation: Division of Transplantation, Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.
authors.forename: Tayyab S
authors.initials: TS
authors.lastname: Diwan
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015992:Body Mass Index; D015897:Comorbidity; D016208:Databases, Factual; D051799:Delayed Graft Function / Q000453:epidemiology*; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009765:Obesity / Q000453:epidemiology*; D050177:Overweight / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013851:Thinness / Q000453:epidemiology*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus
keywords: complications; delayed graft function; live donors; obesity; outcome; rejection